News
RGLS
1.505
+5.99%
0.085
Weekly Report: what happened at RGLS last week (0219-0223)?
Weekly Report · 1d ago
Weekly Report: what happened at RGLS last week (0212-0216)?
Weekly Report · 02/19 10:27
Weekly Report: what happened at RGLS last week (0205-0209)?
Weekly Report · 02/12 10:20
Optimistic Buy Rating for Regulus Based on Promising Phase 1b Trial Prospects in ADPKD Treatment
TipRanks · 02/09 13:18
Weekly Report: what happened at RGLS last week (0129-0202)?
Weekly Report · 02/05 10:25
Weekly Report: what happened at RGLS last week (0122-0126)?
Weekly Report · 01/29 10:19
Weekly Report: what happened at RGLS last week (0115-0119)?
Weekly Report · 01/22 10:21
Regulus Therapeu: Statement of changes in beneficial ownership of securities
Press release · 01/19 02:16
Regulus Therapeu: [Amend]Statement of acquisition of beneficial ownership by individuals
Press release · 01/18 18:11
Weekly Report: what happened at RGLS last week (0108-0112)?
Weekly Report · 01/15 10:19
Regulus Therapeu: Securities to be offered to employees in employee benefit plans
Press release · 01/12 23:40
Regulus Therapeu: Notice of Effectiveness
Press release · 01/10 12:14
Weekly Report: what happened at RGLS last week (0101-0105)?
Weekly Report · 01/08 10:21
Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Ultragenyx Pharmaceutical (RARE) and Regulus (RGLS)
TipRanks · 01/04 11:30
More
Webull provides a variety of real-time RGLS stock news. You can receive the latest news about Regulus Therapeu through multiple platforms. This information may help you make smarter investment decisions.
About RGLS
Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing drugs targeting microRNAs to treat diseases. The Company is leveraging its oligonucleotide drug discovery and development to develop a pipeline complemented by a rich intellectual property estate in the microRNA field. The Company’s lead product candidate includes RGLS8429. The Company is developing single-stranded oligonucleotides, which are chemically synthesized chains of nucleotides that are complementary to (thereby pairing with) the target microRNA. RGLS8429 is an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD). RGLS8429 maintains beneficial attributes, such as preferential kidney exposure and similar PK profile, miR-17 inhibition potency and duration of action in the kidney, equal potency in vitro and in vivo efficacy studies.